Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Academisch Ziekenhuis Leiden patents


Recent patent applications related to Academisch Ziekenhuis Leiden. Academisch Ziekenhuis Leiden is listed as an Agent/Assignee. Note: Academisch Ziekenhuis Leiden may have other listings under different names/spellings. We're not affiliated with Academisch Ziekenhuis Leiden, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Academisch Ziekenhuis Leiden-related inventors


Means and methods for treating facioscapulohumeral muscular dystrophy (fshd).

The invention is related to facioscapulohumeral muscular dystrophy (fshd) and in particular therapeutic means and methods for the treatment of the disease. In one aspect the invention provides a composition for use in the treatment of a subject that has fshd which composition has a therapeutically effective amount of a substance which increases the level and/or activity of a protein encoded by a structural maintenance of chromosomes flexible hinge domain containing 1 (smchd1) gene in cells of the subject. ... Academisch Ziekenhuis Leiden

Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines

The present invention relates to novel cd4+ and cd8+ t cell epitopes that are specific for hpv-specific e6 and e7 oncoproteins, to peptides comprising these novel t cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of hpv related diseases. Preferred epitopes are recognized by a t cell that infiltrates a cervical neoplastic lesion or by a t cell from a draining lymph node, and are presented by an hla-dq or hla-dp molecule, or an hla-b.. ... Academisch Ziekenhuis Leiden

Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses

Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal t cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (myco) bacterially and/or virally infected cells or tumor cells. ... Academisch Ziekenhuis Leiden

Methods of inducing exon skipping

Oligonucleotides for inducing exon skipping, including exon 51 of the dystrophin gene. Compositions are disclosed for treating duchenne muscular dystrophy. ... Academisch Ziekenhuis Leiden

Methods of inducing exon skipping

Methods for inducing skipping of exons, including exon 51 of the dystrophin gene. Oligonucleotides are used for inducing exon skipping and for treating duchenne muscular dystrophy. ... Academisch Ziekenhuis Leiden

Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations

The disclosure provides among others a combination of a vaccine and a cd94/nkg2a and/or a cd94/nkg2b binding antibody for use in the treatment of a subject in need thereof, wherein said vaccine comprises an immunogen for eliciting an immune response against an antigen or a nucleic acid molecule encoding said immunogen.. . ... Academisch Ziekenhuis Leiden

Anti-carbamylated protein antibodies and the risk for arthritis

Antibodies against citrullinated protein antigens (acpa) have shown their relevance for the diagnosis and possibly pathogenesis in arthritis. Described are means and methods for determining antibodies against homocitrulline-containing proteins or carbamylated proteins/peptides (anti-carp) for the classification of individuals suffering from, or at risk of suffering from, arthritis.. ... Academisch Ziekenhuis Leiden

Antisense oligonucleotide directed removal of proteolytic cleavage sites, the hchwa-d mutation, and trinucleotide repeat expansions

Described are methods for removing a proteolytic cleavage site, the hchwa-d mutation or the amino acids encoded by a trinucleotide repeat expansion from a protein comprising providing a cell that expresses pre-mrna encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that comprises the proteolytic cleavage site, hchwa-d mutation or trinucleotide repeat expansion, respectively, the method further comprising allowing translation of mrna produced from the pre-mrna.. . ... Academisch Ziekenhuis Leiden

Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins

The invention relates to means and methods for removing a proteolytic cleavage site from a protein comprising providing a cell that expresses pre-mrna encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that encodes the proteolytic cleavage site, the method further comprising allowing translation of mrna produced from the pre-mrna.. . ... Academisch Ziekenhuis Leiden

Prohemostatic proteins for the treatment of bleeding

This disclosure relates to recombinant fxa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor xa inhibitor. Disclosed herein are recombinant factor xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject.. ... Academisch Ziekenhuis Leiden

Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna

The invention relates to a method for inducing or promoting skipping of exon 45 of dmd pre-mrna in a duchenne muscular dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing an isolate muscle cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such molecule used in the method.. ... Academisch Ziekenhuis Leiden

Vascular re-modelling

The present invention is based on the finding that microrna from the microrna gene cluster located on the human chromosomal at locus 14q32 play an important role in vascular development and re-modelling. Modulators of any of the 14q32 microrna may be exploited as a means to modulate vascular re-modelling processes and/or in the treatment and/or prevention of vascular disorders or disease.. ... Academisch Ziekenhuis Leiden

Methods and means for efficient skipping of at least one of the following exons of the human duchenne muscular dystrophy gene: 43, 46, 50-53

The invention relates a method wherein a molecule is used for inducing and/or promoting skipping of at least one of exon 43, exon 46, exons 50-53 of the dmd pre-mrna in a patient, preferably in an isolated cell of a patient, the method comprising providing said cell and/or said patient with a molecule. The invention also relates to said molecule as such.. ... Academisch Ziekenhuis Leiden








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Academisch Ziekenhuis Leiden in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Academisch Ziekenhuis Leiden with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###